Randomized control trial to validate mitigation of chemotherapy-induced peripheral neuropathy by limb-cooling apparatus in breast cancer patients receiving paclitaxel (CECILIA). This is an ASCO ...

A recent research study found that a combination of the GLP-1 receptor agonist semaglutide and bimagrumab, an antibody that ...

An analysis led by Mass General Brigham investigators found slower aging in older adults after two years of a daily multivitamin, with greater benefits for those who began the trial with accelerated b ...

Multivitamins are the most common dietary supplement in the U.S. People take these pills (or gummies, indeed) for a variety of health reasons, but the science on what multivitamins may do for your ...

A randomized phase 2 peri-operative (neoadjuvant plus adjuvant) study of fianlimab (anti–LAG-3) plus cemiplimab (anti–PD-1) versus anti–PD-1 alone in patients with resectable stage III and IV melanoma ...

A study has found that taking daily multivitamins may slow the aging process. The research team from Brigham and Women’s Hospital, Harvard Medical School, published their analysis comparing ...

Low dose alnodesertib plus gemcitabine met the primary endpoint of progression-free survival (PFS) versus gemcitabine alone ...

Bioxytran, Inc. (OTCQB:BIXT), a clinical-stage biotechnology company developing carbohydrate-based therapeutics, today ...

Controlled study designed to confirm previous compelling efficacy with preliminary data expected by the end of 2026 Pelareorep-based treatment regimen recently granted Fast Track Designation in 2L ...

Evidence continues to mount suggesting that GLP-1 drugs like Ozempic and Wegovy may help people cut back on cigarettes, drinking and opioid use disorders and addiction.